VMD-928 is under clinical development by VM Discovery and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VMD-928’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VMD-928 is under development for the treatment of lymphoma, thymic carcinoma, thymoma, pancreatic cancer and mesothelioma, head and neck squamous cell carcinoma, ovarian cancer, hepatocellular carcinoma, squamous cell carcinoma of lung (squamous NSCLC), esophageal cancer, adenoid cystic carcinoma, prostate cancer, cervical cancer, gastric cancer, melanoma, acute myeloid leukemia, pancreatic carcinoma and non-Hodgkins' lymphoma. It is formulated as a capsule and administered through oral route. The drug candidate acts by targeting tropomyosin receptor kinase A (TrkA).
For a complete picture of VMD-928’s drug-specific PTSR and LoA scores, buy the report here.